On Friday, AstraZeneca ADR AZN reached a noteworthy performance benchmark, seeing its Relative Strength (RS) Rating jump into ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

U.S. infectious disease expert Anthony Fauci said on Wednesday that AstraZeneca's decision to pause global trials of its ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.